177 related articles for article (PubMed ID: 2095478)
1. [The use of magnetic fields in ophthalmology].
Skrinnik AV; Moiseeva NN
Oftalmol Zh; 1990; (8):492-6. PubMed ID: 2095478
[No Abstract] [Full Text] [Related]
2. [Electrotherapy in ophthalmology. Iontophoresis].
Sobecki R
Klin Oczna; 1988 Feb; 90(2):71-3. PubMed ID: 3411899
[No Abstract] [Full Text] [Related]
3. [Kinetics of drugs in ophthalmology].
Lapalus P; Moulin G; Fredj D
Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():31-48. PubMed ID: 2866043
[No Abstract] [Full Text] [Related]
4. [Use of prenacide magnetophoresis in complex treatment of some ocular diseases].
Alekseev BN; Tikhomirova TV
Vestn Oftalmol; 2003; 119(5):47-8. PubMed ID: 14598498
[No Abstract] [Full Text] [Related]
5. [Endonasal electrophoresis in ophthalmology].
Kulieva IA
Vopr Kurortol Fizioter Lech Fiz Kult; 2000; (4):43-5. PubMed ID: 11008577
[No Abstract] [Full Text] [Related]
6. Use of drugs in the eye.
Ellis PP
GP; 1968 Oct; 38(4):99-108. PubMed ID: 5679524
[No Abstract] [Full Text] [Related]
7. Randomizing 1 eye or 2 eyes: a missed opportunity.
Glassman AR; Melia M
JAMA Ophthalmol; 2015 Jan; 133(1):9-10. PubMed ID: 25256889
[No Abstract] [Full Text] [Related]
8. Considerations for randomizing 1 eye or 2 eyes.
Bunce C; Wormald R
JAMA Ophthalmol; 2015 Oct; 133(10):1221. PubMed ID: 26291489
[No Abstract] [Full Text] [Related]
9. Considerations for randomizing 1 eye or 2 eyes--reply.
Glassman AR; Melia M
JAMA Ophthalmol; 2015 Oct; 133(10):1221. PubMed ID: 26291566
[No Abstract] [Full Text] [Related]
10. [Side effects of drugs in ophthalmology].
Polak BC; Henkes HE
Ned Tijdschr Geneeskd; 1987 Dec; 131(49):2254-7. PubMed ID: 3696257
[No Abstract] [Full Text] [Related]
11. [Penicillin iontophoresis in ophthalmology].
Fellner R; Glawogger F
Klin Monbl Augenheilkd; 1972 Mar; 160(3):300-3. PubMed ID: 5025501
[No Abstract] [Full Text] [Related]
12. [Homogeneous functional group, value--added tax, eye drops and ocular injections, personal computer and secundum artem].
Recio Blázquez ML
Farm Hosp; 2004; 28(4):291-3. PubMed ID: 15369440
[No Abstract] [Full Text] [Related]
13. Ophthalmic drug delivery: development and regulatory considerations.
Novack GD
Clin Pharmacol Ther; 2009 May; 85(5):539-43. PubMed ID: 19225448
[No Abstract] [Full Text] [Related]
14. Treatment of lacrimal deficiencies. Mechanical devices.
Doane MG
Int Ophthalmol Clin; 1973; 13(1):239-44. PubMed ID: 4724260
[No Abstract] [Full Text] [Related]
15. [New devices for the electrophoretic diagnosis and treatment of eye diseases].
Kiselev GA; Lebedev OI
Oftalmol Zh; 1988; (3):189-92. PubMed ID: 3186127
[No Abstract] [Full Text] [Related]
16. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
Myles ME; Neumann DM; Hill JM
Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
[TBL] [Abstract][Full Text] [Related]
17. Eyes on New Product Development.
Novack GD
J Ocul Pharmacol Ther; 2017 Mar; 33(2):65. PubMed ID: 28099041
[No Abstract] [Full Text] [Related]
18. [Magnetophoresis with the use of ophthalmic drug films in corneal microtrauma].
Shif LV; Novikov IaS; Tanova RM; Kambarova LI
Oftalmol Zh; 1989; (6):377-8. PubMed ID: 2622609
[No Abstract] [Full Text] [Related]
19. Drug delivery to the eye: current trends and future perspectives.
Behar-Cohen F
Ther Deliv; 2012 Oct; 3(10):1135-7. PubMed ID: 23116006
[No Abstract] [Full Text] [Related]
20. [Various application forms of synthetics in ophthalmology. Synthetics in ophthalmological drug therapy].
Heilmann K
Ber Zusammenkunft Dtsch Ophthalmol Ges; 1978; (75):293-7. PubMed ID: 743112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
